New Zealand markets closed

Calidi Biotherapeutics, Inc. (CLDI)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
0.2320-0.0070 (-2.93%)
At close: 04:00PM EDT
0.2442 +0.01 (+5.26%)
Pre-market: 05:20AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 11.70M
Enterprise value 16.99M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)50.83
Price/book (mrq)N/A
Enterprise value/revenue 49.42
Enterprise value/EBITDA -0.63

Trading information

Stock price history

Beta (5Y monthly) 0.57
52-week change 3-97.75%
S&P500 52-week change 326.43%
52-week high 313.7900
52-week low 30.1440
50-day moving average 30.4486
200-day moving average 32.8828

Share statistics

Avg vol (3-month) 31.05M
Avg vol (10-day) 32.45M
Shares outstanding 548.96M
Implied shares outstanding 648.96M
Float 822.07M
% held by insiders 154.95%
% held by institutions 17.84%
Shares short (15 Apr 2024) 41.43M
Short ratio (15 Apr 2024) 42.47
Short % of float (15 Apr 2024) 45.94%
Short % of shares outstanding (15 Apr 2024) 44.01%
Shares short (prior month 15 Mar 2024) 4147.28k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-287.25%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -28.6M
Net income avi to common (ttm)-29.22M
Diluted EPS (ttm)-1.7300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.95M
Total cash per share (mrq)0.05
Total debt (mrq)7.24M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.42
Book value per share (mrq)-0.23

Cash flow statement

Operating cash flow (ttm)-26.98M
Levered free cash flow (ttm)-43.96M